Current status of nonsteroidal anti-inflammatory drugs in physiatry: Balancing risks and benefits in pain management

American Journal of Physical Medicine and Rehabilitation

Volumn 84, Issue 11, 2005, Pages 885-894

  Kaplan, Robert J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesics; Anti Inflammatory Agents; Arthritis; Coronary Disease; Cyclooxygenase Inhibitors; Musculoskeletal Diseases; Nonsteroidal

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB;

ALZHEIMER DISEASE; ANALGESIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON POLYP; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ANALYSIS; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; PAIN; PAIN ASSESSMENT; PHYSICAL MEDICINE; PRACTICE GUIDELINE; REVIEW; STOMACH DISEASE; SYSTEMATIC REVIEW; THROMBOGENESIS; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EVIDENCE-BASED MEDICINE; GASTRITIS; GASTROINTESTINAL DISEASES; HUMANS; MAXIMUM TOLERATED DOSE; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS;

EID: 27544437410     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.phm.0000184155.77034.20     Document Type: Review

References (55)

1. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99
2. Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000;343:1520-8
3. Silverstein FE, Faich G, Goldstein JL, et al: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study. A randomized controlled trial. JAMA 2000;284:1247-55
4. US Food and Drug Administration: NDA 21-042, s007, Vioxx Gastrointestinal Safety: Medical Officer Review, 2000. Available at: http://www.fda.gOv/ohrms/ dockets/ac/01/briefing/3677b2_03_med.doc. Accessed December 20, 2001
5. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9
6. FitzGerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42
7. Mamdani M, Rochon P, Juurlink DN, et al: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6
8. Bresalier RS, Sandier RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial: Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. N Engl J Med 2005;352:1092-102
9. Topol EJ: Failing the public health: Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1717-9
10. FitzGerald GA: Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11
11. Juni P, Nartey L, Reichenbach S, et al: Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004;364:2021-9
12. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention: Adenoma Prevention with Celecoxib (APC) Study Investigators. N Engl J Med 2005;352: 1071-80
13. Nussmeier NA, Whelton AA, Brown MT, et al: Complications of the COX-2 inhibitors Parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91
14. The Food and Drug Administration (FDA): FDA Talk Paper: FDA Issues Public Health Advisory Recommending Limited Use of Cox-2 Inhibitors. T04-61. Available at: http://www. fda.gov/bbs/topics/ANSWERS/2004/ANS01336.html. Accessed December 23, 2004
15. Ray WA, Stein CM, Stein Daugherty JR, et al: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3
16. Solomon DH, Schneeweiss S, Glynn RJ, et al: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109: 2068-73
17. Farkouh ME, Kirshner H, Harrington RA, et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. TARGET Study Group. Lancet 2004;364: 675-84
18. Garcia Rodriquez LA, Varas-Lorenzo C, Maguire A, et al: Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109:3000-6
19. American College of Rheumatology: Hot Line: The Safety of COX-2 Inhibitors Deliberations from the February 16-18, 2005, FDA Meeting. Available at: http://www.rheumatology. org/publications/hotline/0305NSAIDs.asp. Accessed April 28, 2005
20. Center for Drug Evaluation and Research: Analysis and Recommendations for Agency Action Regarding Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Risk. Available at: http://www.fda.gov/cder/drug/infopage/COX2/ NSAIDdecisionMemo.pdf. Accessed April 6, 2005
21. J1 Investigator Presentation-Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)-Constantine Lyketsos MD. Available at: http://www.masterdocs.com/cox-2.htm. Accessed April 30, 2005
22. J2 Committee Questions to Dr Lyketsos. Available at: http://www. masterdocs.com/cox-2.htm. Accessed April 30, 2005
23. Konstantinopoulos PA, Lehmann DF: The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: Comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005;45:742-50
24. Catella-Lawson F, Reilly MP, Kapoor SC, et al: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17
25. MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4
26. van Ryn J, Kink-Eiband M, Kuritsch I, et al: Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004;44:777-84
27. Patel TN, Goldberg KC: Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 2004;164:852-6
28. Kurth T, Glynn RJ, Walker AM, et al: Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 2003;108: 1191-5
29. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366
30. Schechter S: Naproxen's interaction with aspirin may affect its cardioprotective effect. Arch Intern Med 2003;163:1374
31. Mukherjee D, Nissen SE, Topol EJ: Lack of cardioprotective effect of naproxen. N Engl J Med 2002;162:2637
32. Bennett JS, Daugherty A, Herrington D, et al: The use of nonsteroidal anti-inflammatory drugs (NSAIDs): A science advisory from the American Heart Association. Circulation 2005;111:1713-6
33. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15
34. Stupnicki T, Dietrich K, Gonzalez-Carro P, et al: Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003;68: 198-208
35. Rostom A, Dube C, Wells G, et al: Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;4:CD002296
36. Graham DY, Agrawal NM, Campbell DR, et al: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind randomized, multicenter, active- and placebo-controlled study of misoprostol versus lansoprazole. NSAID-Associated Gastric Ulcer Prevention Study Group. Arch Intern Med 2002;162:169-75
37. Hooper L, Brown TJ, Elliot R, et al: The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs. BMJ 2004;329:948
38. Pilotto A, Franceschi M, Leandro G, et al: Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004;20:1091-7
39. Reig E: Tramadol in musculoskeletal pain: A survey. Clin Rheumatol 2002;21(suppl 1):S9-11
40. Podichetty VK, Mazanec DJ, Biscup RS: Chronic non-malignant musculoskeletal pain in older adults: Clinical issues and opioid intervention. Postgrad Med J 2003;79:627-33
41. Gambaro G, Perazella MA: Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253: 643-52
42. Bleumink GS, Feenstra J, Sturkenboom MC, et al: Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003;63:525-34
43. Armstrong EP, Malone DC: The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 2003;25:1-18
44. Berman BM: Integrative approaches to pain management: How to get the best of both worlds. BMJ 2003;326:1320-1
45. Wright A, Sluka KA: Nonpharmacological treatments for musculoskeletal pain. Clin J Pain 2001;17:33-46
46. Stovitz SD, Johnson RJ: NSAIDs and musculoskeletal treatment: what is the clinical evidence? Physician Sports Med 2003;31:35-40
47. NSAIDs, Coxibs, Smoking, and Bone. Bandolier Extra, 2004. Available at: http://www.jr2.ox.ac.uk/bandolier/booth/pain-pag/wisdom/NSAIbone.html. Accessed May 5, 2005
48. Reuben SS: Considerations in the use of COX-2 inhibitors in spinal fusion surgery. Anesth Analg 2001;93:798-804
49. Simon AM, Manigrasso MB, O'Connor JP: Cyclooxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-76
50. Wheeler P, Batt ME: Do non-steroidal anti-inflammatory drugs adversely affect stress fracture healing? A short review. Br J Sports Med 2005;39:65-9
51. Bhattacharyya T, Levin R, Vrahas MS, et al: Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum 2005;53:364-7
52. Schnitzer TJ, Popovich JM, Andersson GB, et al: Effect of piroxicam on gait in patients with osteoarthritis of the knee. Arthritis Rheum 1993;36:1207-13
53. Elder CL, Dahners LE, Weinhold PS: A cyclooxygenase-2 inhibitor impairs ligament healing in the rat. Am J Sports Med 2001;29:801-5
54. Riley GP, Cox M, Harrall RL, et al: Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro. J Hand Surg (Br) 2001;26:224-8
55. Simon LS, Lipman AG, Caudill-Slosberg M, et al: Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis, ed 2. Glenview, IL, American Pain Society, 2002